Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Peripheral Nervous System Diseases Chemotherapy-induced Peripheral Neuropathy Nervous System Diseases Neuromuscular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Alta Bates Comprehensive Cancer Center, Berkeley, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy.
Sensory or motor neuropathy must be >/= grade 2 per Common Toxicity Criteria at baseline.
In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable.
Patient must have normal hematological cell counts.
Patient must have a life expectancy of >/= 3 months.

Treatment and study plan

leteprinim potassium (Neotrofin)

Drug

Sponsors and collaborators

Lead sponsor

NeoTherapeutics

Industry

Registry information

Official study title

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer

Important dates

Study start: 2002
First posted: Jul 19, 2002
Registry last updated: Jun 24, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed